OTS-412
AXP000107.1 · Oncolytic virus
- Platform
- vaccinia virus (thymidine kinase-deleted)
- Originator
- Bionoxx
- Sponsor
- Bionoxx
Names
| Name | Type | Source |
|---|---|---|
| OTS-412 | preferred name, code | curator, ctgov |
Virus
- Role
- Oncolytic
- Family
- Poxviridae
- Virus
- vaccinia virus (NCBI Taxonomy 10245)
- Replication
- conditionally replicating
- Modifications
- thymidine kinase deleted (reported)
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (3)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07170592 | A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients | Not yet recruiting | Phase 1 | 2027-01 | 2028-12 | 24 | Treatment-Refractory Solid Tumors |
| NCT07190833 | A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea) | Recruiting | Phase 1 | 2026-03-09 | 2028-12 | 21 | Treatment-Refractory Solid Tumors |
| NCT07302945 | A Single-volunteer Study of Immune Response Following OTS-412 Vaccinia Virus Systemic Injection(Self-experiment) | Completed | Early phase 1 | 2022-01-04 | 2022-01-14 | 1 | Healthy Volunteer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 31963415 | Engineering and Characterization of Oncolytic Vaccinia Virus Expressing Truncated Herpes Simplex Virus Thymidine Kinase. | Cancers | 2020 | name in abstract: OTS-412 |
| PMID 33081279 | Engineering and Preclinical Evaluation of Western Reserve Oncolytic Vaccinia Virus Expressing A167Y Mutant Herpes Simplex Virus Thymidine Kinase. | Biomedicines | 2020 | name in abstract: OTS-412 |
Notes
Korean oncolytic vaccinia given with hydroxyurea; earlier phase 1 work in Korea and a phase 1 with hydroxyurea/atezolizumab (NCT07190833, recruiting). Construct details and route not confirmed.
How to cite
OTS-412 (AXP000107.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000107.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.